Kytril

Granisetron, the active ingredient in Kytril, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings, acting on both peripheral and central pathways.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory compliance across diverse markets.

Kytril (granisetron) is used to control nausea and vomiting mediated by serotonin pathways.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea caused by cytotoxic agents. Postoperative nausea and vomiting: helps prevent and treat nausea after surgical procedures. Radiation‑induced nausea and vomiting: alleviates nausea associated with radiation therapy.

Granisetron may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: occasional light‑headedness. - Fatigue: feeling of tiredness. - Diarrhea: loose stools. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, difficulty breathing. - QT interval prolongation: potential for cardiac conduction disturbances. - Serotonin syndrome: rare, with agitation, hyperreflexia, fever. - Hepatic dysfunction: abnormal liver enzymes.

Before prescribing Kytril, clinicians should consider several safety aspects. - Cardiac assessment: evaluate history of arrhythmias or prolonged QT. - Electrolyte monitoring: correct hypokalemia or hypomagnesemia. - Hepatic function: adjust use in patients with severe liver impairment. - Concomitant QT‑prolonging drugs: avoid or monitor closely. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original pack, protect from moisture.

Granisetron can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive anti‑emetic effect may increase risk of QT prolongation. - Amiodarone or other anti‑arrhythmics: heightened risk of cardiac conduction abnormalities. - Apomorphine: may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Opioids: may enhance sedation or constipation. - Anticholinergic agents: may worsen dry mouth.